Kappos L - Search Results

1

Atorvastatin added to interferon beta for relapsing multiple sclerosis: 12-month treatment extension of the randomized multicenter SWABIMS trial.

Kamm CP, El-Koussy M, Humpert S, Findling O, Burren Y, Schwegler G, Donati F, Müller M, Müller F, Slotboom J, Kappos L, Naegelin Y, Mattle HP; SWABIMS Study Group. Kamm CP, et al. Among authors: kappos l. PLoS One. 2014 Jan 30;9(1):e86663. doi: 10.1371/journal.pone.0086663. eCollection 2014. PLoS One. 2014. PMID: 24497963 Free PMC article. Clinical Trial.

2

Treatment of multiple sclerosis with 15 +/- deoxyspergualin. Design of a controlled study with close MRI-monitoring.

Kappos L, Radü EW, Bernasconi L, Brunnschweiler H, Hartung HP, Haas J, Gehlen W, Hartard C, Lagreze HL, Rüttinger H, et al. Kappos L, et al. Schweiz Arch Neurol Psychiatr (1985). 1993;144(3):198-201. Schweiz Arch Neurol Psychiatr (1985). 1993. PMID: 7687364 Clinical Trial.

3

Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial.

Polman CH, Dahlke F, Thompson AJ, Ghazi M, Kappos L, Miltenburger C, Pozilli C. Polman CH, et al. Among authors: kappos l. Mult Scler. 1995;1 Suppl 1:S51-4. Mult Scler. 1995. PMID: 9345400 Clinical Trial.

4

Interferon beta in the treatment of multiple sclerosis--closing remarks.

Kappos L. Kappos L. Mult Scler. 1995;1 Suppl 1:S64-6. Mult Scler. 1995. PMID: 9345403 Review. No abstract available.

5

Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study.

Polman C, Barkhof F, Kappos L, Pozzilli C, Sandbrink R, Dahlke F, Jakobs P, Lorenz A; European Oral Interferon Beta-1a in Relapsing-Remitting MS Study Group. Polman C, et al. Among authors: kappos l. Mult Scler. 2003 Aug;9(4):342-8. doi: 10.1191/1352458503ms923oa. Mult Scler. 2003. PMID: 12926838 Clinical Trial.

6

Effect of drugs in secondary disease progression in patients with multiple sclerosis.

Kappos L. Kappos L. Mult Scler. 2004 Jun;10 Suppl 1:S46-54; discussion S54-5. doi: 10.1191/1352458504ms1030oa. Mult Scler. 2004. PMID: 15218809 Review.

7

Interferons in multiple sclerosis.

Kappos L. Kappos L. Neurol Clin. 2005 Feb;23(1):189-214, vii-viii. doi: 10.1016/j.ncl.2004.10.004. Neurol Clin. 2005. PMID: 15661094 Review. No abstract available.

8

Genomics and proteomics: role in the management of multiple sclerosis.

Kappos L, Achtnichts L, Dahlke F, Kuhle J, Naegelin Y, Sandbrink R, Lindberg RL. Kappos L, et al. J Neurol. 2005 Sep;252 Suppl 3:iii21-iii27. doi: 10.1007/s00415-005-2013-3. J Neurol. 2005. PMID: 16170496 Review.

9

Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis.

Weder C, Baltariu GM, Wyler KA, Gober HJ, Lienert C, Schluep M, Radü EW, De Libero G, Kappos L, Duda PW. Weder C, et al. Among authors: kappos l. Eur J Neurol. 2005 Nov;12(11):869-78. doi: 10.1111/j.1468-1331.2005.01084.x. Eur J Neurol. 2005. PMID: 16241976

10

Oral fingolimod (FTY720) for relapsing multiple sclerosis.

Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW; FTY720 D2201 Study Group. Kappos L, et al. N Engl J Med. 2006 Sep 14;355(11):1124-40. doi: 10.1056/NEJMoa052643. N Engl J Med. 2006. PMID: 16971719 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

807 results

Search Page

Filters